Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease
Takudzwa Mkorombindo, Mark T DransfieldLung Health Center, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USAAbstract: Despite maximal medical therapy, a subset of patients with chronic obstructive pulmonary dis...
Main Authors: | Mkorombindo T, Dransfield MT |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-08-01
|
Series: | International Journal of COPD |
Subjects: | |
Online Access: | https://www.dovepress.com/mepolizumab-in-the-treatment-of-eosinophilic-chronic-obstructive-pulmo-peer-reviewed-article-COPD |
Similar Items
-
Variability of Blood Eosinophil Count at Stable-State in Predicting Exacerbation Risk of Chronic Obstructive Pulmonary Disease
by: Kwok WC, et al.
Published: (2023-06-01) -
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
by: Haldar P
Published: (2017-06-01) -
Relationship between Peripheral Blood Eosinophil Count and Neutrophil/Lymphocyte Ratio with Number of Attacks Leading to Hospital Admission in Chronic Obstructive Pulmonary Disease
by: Maryam Mirzaee, et al.
Published: (2020-12-01) -
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
by: Steven W. Yancey, et al.
Published: (2019-09-01) -
Correlation between FEV1% Predicted and Blood Eosinophils in Patients with Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)
by: Alfian Nurfaizi, et al.
Published: (2021-05-01)